Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study
- PMID: 17066483
- DOI: 10.1002/ana.20976
Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study
Abstract
Objective: To determine whether prespecified baseline magnetic resonance imaging (MRI) profiles can identify stroke patients who have a robust clinical response after early reperfusion when treated 3 to 6 hours after symptom onset.
Methods: We conducted a prospective, multicenter study of 74 consecutive stroke patients admitted to academic stroke centers in North America and Europe. An MRI scan was obtained immediately before and 3 to 6 hours after treatment with intravenous tissue plasminogen activator 3 to 6 hours after symptom onset. Baseline MRI profiles were used to categorize patients into subgroups, and clinical responses were compared based on whether early reperfusion was achieved.
Results: Early reperfusion was associated with significantly increased odds of achieving a favorable clinical response in patients with a perfusion/diffusion mismatch (odds ratio, 5.4; p = 0.039) and an even more favorable response in patients with the Target Mismatch profile (odds ratio, 8.7; p = 0.011). Patients with the No Mismatch profile did not appear to benefit from early reperfusion. Early reperfusion was associated with fatal intracranial hemorrhage in patients with the Malignant profile.
Interpretation: For stroke patients treated 3 to 6 hours after onset, baseline MRI findings can identify subgroups that are likely to benefit from reperfusion therapies and can potentially identify subgroups that are unlikely to benefit or may be harmed.
Comment in
-
Is penumbral imaging useful for extending the treatment window for intravenous tissue plasminogen activator?Ann Neurol. 2006 Nov;60(5):499-501. doi: 10.1002/ana.21043. Ann Neurol. 2006. PMID: 17120251 No abstract available.
-
MRI-based thrombolytic therapy in acute stroke: finally, the proof of concept by DEFUSE.Nat Clin Pract Neurol. 2007 Jul;3(7):370-1. doi: 10.1038/ncpneuro0529. Epub 2007 Jun 5. Nat Clin Pract Neurol. 2007. PMID: 17551545 No abstract available.
-
Magnetic resonance imaging profiles predict clinical response to early reperfusion: the DEFUSE study.Curr Atheroscler Rep. 2007 Oct;9(4):258-9. doi: 10.1007/s11883-007-0030-7. Curr Atheroscler Rep. 2007. PMID: 18173950 No abstract available.
References
-
- Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
-
- Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-774.
-
- Zweifler RM, Brody ML, Graves GC, et al. Intravenous t-PA for acute ischemic stroke: therapeutic yield of a stroke code system. Neurology 1998; 50: 501-503.
-
- Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic Therapy in Acute Ischemic Stroke Study investigators. Stroke 2000; 31: 811-816.
-
- Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282: 2019-2026.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources